Inhibikase Therapeutics, Inc. (IKT)

Nasdaq: IKT · Biological Products, (No Diagnostic Substances) · Wilmington, DE · filing with the SEC since 2018

Full chart Alerts Compare

Grade4.3

◀ Past 2.4● Present 4.1▶ Future 5.7

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Who owns Inhibikase Therapeutics, Inc.

As filed with the SEC

Holders of 5% or more

RA Capital Management, L.P. holds 9.9% of Common Stock, $0.001 par value per share, as its SCHEDULE 13G/A filed Jul 31, 2026 says.

Directors and officers

report now, of 17 people on the record since 2020. Their holdings as a group are not read here.

Institutions as a whole

n/a

The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.

Holders of 5% or moreshare of the class, as filed

RA Capital Management, L.P.

SCHEDULE 13G/A · filed Jul 31, 2026 · Common Stock, $0.001 par value per share · 15.9% in Jul 17, 2026

9.9%

Commodore Capital LP

SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.001 par value

9.9%

ADAR1 Capital Management, LLC

SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.001 par value · 9.9% in Feb 17, 2026

9.9%

Fairmount Funds Management LLC

SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.001 per share · 9.9% in Feb 14, 2025

9.9%

Sands Capital Life Sciences Pulse Fund II, L.P.

SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, $0.001 par value per share · 10.8% in Feb 13, 2026

9.3%

Perceptive Advisors LLC

SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value · 8.9% in May 15, 2026

6.9%

Trails Edge Capital Partners, LP

SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.001 par value · 5.1% in Dec 31, 2025

6.1%

Blackrock, Inc.

SCHEDULE 13G · filed Jul 28, 2026 · Common Stock

5.9%

Armistice Capital, LLC

SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.001 par value · reported falling below 5%

under 5%

Nantahala Capital Management, LLC

SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value · reported falling below 5%, from 5.68% in Feb 13, 2026

under 5%

Point72 Asset Management, L.P.

SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%

under 5%

What IKT reports owning in othersstakes of 5% or more, and other ties

Other ties the annual report names

Cor Hepta

A company bought · asset acquisition · owns, named in the 10-K filed Mar 26, 2026

CorHepta Pharmaceuticals

A company bought · acquisition · owns, named in the 10-K filed Mar 26, 2026

2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 27, 2025.

Insider tradesForm 4

0sales

0purchases

0sales on a scheduled plan

0people selling

$0sold, in dollars

$0bought, in dollars

Open-market trades on Form 4 from Oct 21, 2025 to Oct 21, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.

By calendar yearSoldBought

212224

2024 runs to Oct 21, 2026. Dollars as filed, summed by the transaction date.

People who traded in the window1 of 25 on the roster

Person	Role as filed	Sales	Sold	On a plan	Buys	Bought
Sands Frank M.	10% owner	0	$0	0	1	$3.0M

SI Assistanton IKT · research, not advice